2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology
- 15 June 2002
- journal article
- guideline
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (12) , 2895-2903
- https://doi.org/10.1200/jco.2002.04.178
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of TreatmentJournal of Clinical Oncology, 2000
- Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk FactorsJournal of Clinical Oncology, 1999
- American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy ProtectantsJournal of Clinical Oncology, 1999
- Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.Journal of Clinical Oncology, 1998
- Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.Journal of Clinical Oncology, 1998
- Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.Journal of Clinical Oncology, 1998
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology, 1997
- Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.Journal of Clinical Oncology, 1997
- A Pharmacoeconomic Evaluation of the Use of Dexrazoxane in Preventing Anthracycline-Induced Cardiotoxicity in Patients with Stage IIIB or IV Metastatic Breast CancerClinical Therapeutics, 1997
- Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.Journal of Clinical Oncology, 1996